MBRX.US Moleculin Biotech Inc

Healthcare Biotechnology USA Stocks
7.87 USD
Close of Nov 15, 2026
3.23 227.05
Market cap
USD 8.02M
P/E
0.0x
P/B
0.69x
ROE
-248.2%
Dividend yield
1.30%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MBRX.US undervalued?

Graham number

The Graham number of Moleculin Biotech Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Moleculin Biotech Inc fundamental analysis

No fundamental analysis for Moleculin Biotech Inc yet.

Moleculin Biotech Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Moleculin Biotech Inc

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription mo…

Full company profile